


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



C-MER 希瑪

C-MER EYE CARE HOLDINGS LIMITED

希瑪眼科醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3309)

POSITIVE PROFIT ALERT

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of C-MER Eye Care Holdings Limited (the “**Company**” which together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the inside information provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Based on the unaudited financial information currently available for the year ended 31 December 2023 (“**FY2023**”), the Company is expected to realise a turnaround and achieve a profit attributable to the equity holders of the Company in the range of HK\$60.0 million to HK\$65.0 million, as compared with a loss attributable to equity holders of HK\$21.9 million for the year ended 31 December 2022 (“**FY2022**”).

The expected increase in profit attributable to equity holders of the Company was primarily driven by an over 30% increase in revenue generated from medical service to approximately HK\$1,900.0 million in FY2023 from HK\$1,433.6 million in FY2022, partially net off by the reduction in revenue generated from sale of COVID-19 related medical consumables to approximately HK\$19.0 million in FY2023 from HK\$298.3 million in FY2022.

The Group has continued to see a sustained demand on the Group’s ophthalmic and dental service businesses in both Hong Kong and Mainland China, and coupled with the reopening of the border between Hong Kong and Shenzhen, the Group’s dental business in Shenzhen under the brand “Shenzhen CKJ” has recorded a notable revenue growth in FY2023 and a turnaround to profitability.

As the Company is still in the process of finalising the results for FY2023, the information contained in this announcement is based on the management's preliminary review on the management accounts of the Group and current information available to the Board and has not been audited and confirmed by the Company's auditors or the audit committee of the Board. Shareholders and potential investors of the Company are advised to read carefully the annual results announcement of the Company for FY2023 which is expected to be published by the end of March 2024.

Shareholders and prospective investors of the Company are advised to exercise caution when dealings in the shares of the Company.

By order of the Board
C-MER Eye Care Holdings Limited
Dr. LAM Shun Chiu Dennis
Chairman and Chief Executive Officer and Executive Director

Hong Kong, 12 March 2024

As of the date of this announcement, the Board comprises three executive Directors, namely Dr. LAM Shun Chiu Dennis, Ms. LI Xiaoting and Dr. LEE Yau Wing Vincent; and four independent non-executive Directors, namely, Dr. Rex AU YEUNG Pak-kuen, Mr. MA Andrew Chiu Cheung, Mr. IP Shu Kwan Stephen and Mr. YIN Ke.